Webster Jennifer, Jiang Jenny Y, Lu Biao, Xu Fred Y, Taylor William A, Mymin Mathew, Zhang Manna, Minuk Gerald Y, Hatch Grant M
Department of Pharmacology and Therapeutics, Center for Research and Treatment of Atherosclerosis, University of Manitoba, Winnipeg, Canada R3E 0T6.
Biochem J. 2005 Feb 15;386(Pt 1):137-43. doi: 10.1042/BJ20040655.
CL (cardiolipin) is a major mitochondrial membrane phospholipid important for the regulation of mitochondrial function. We examined CL de novo biosynthesis and its resynthesis in isolated rat liver hepatocytes prepared 48 h subsequent to two-thirds PHx (partial hepatectomy). The pool size of CL and its de novo biosynthesis from [1,3-(3)H]glycerol were increased 3.3-fold (P<0.05) and 3.1-fold (P<0.05) respectively in hepatocytes prepared from PHx rats compared with sham-operated controls. The reason for the increased CL biosynthesis was a 65% increase (P<0.05) in enzymic activity in PGP-S (phosphatidylglycerolphosphate synthase), a key enzyme in de novo CL biosynthesis. The increase in PGP-S activity was due to a 3-fold increase (P<0.05) of hepatic PGP-S mRNA expression. The increase in de novo CL biosynthesis and pool size corresponded to a 2.3-fold increase (P<0.05) in the amount of [1-14C]linoleic acid incorporated into CL of hepatocytes prepared from PHx rats compared with sham-operated controls, indicating an increase in CL resynthesis. The activity of MLCL-AT (monolysocardiolipin acyltransferase), a rate-limiting enzyme of CL resynthesis, was increased by 43% (P<0.05) in hepatocytes prepared from PHx rats compared with sham-operated controls; this result would explain the increase in [1-14C]linoleic acid incorporation into CL. The increase in MLCL-AT activity was due to an increase in hepatic MLCL-AT protein expression. The results show that CL de novo biosynthesis and its resynthesis are increased during liver regeneration.
心磷脂(CL)是一种主要的线粒体膜磷脂,对线粒体功能的调节至关重要。我们检测了在三分之二肝部分切除术(PHx)后48小时制备的离体大鼠肝脏肝细胞中CL的从头生物合成及其再合成。与假手术对照组相比,PHx大鼠制备的肝细胞中CL的库大小及其从[1,3-(3)H]甘油的从头生物合成分别增加了3.3倍(P<0.05)和3.1倍(P<0.05)。CL生物合成增加的原因是从头CL生物合成中的关键酶磷脂酰甘油磷酸合酶(PGP-S)的酶活性增加了65%(P<0.05)。PGP-S活性的增加是由于肝脏PGP-S mRNA表达增加了3倍(P<0.05)。从头CL生物合成和库大小的增加对应于与假手术对照组相比,PHx大鼠制备的肝细胞中掺入CL的[1-14C]亚油酸量增加了2.3倍(P<0.05),表明CL再合成增加。与假手术对照组相比,PHx大鼠制备的肝细胞中CL再合成的限速酶单溶血心磷脂酰基转移酶(MLCL-AT)的活性增加了43%(P<0.05);这一结果可以解释[1-14C]亚油酸掺入CL的增加。MLCL-AT活性的增加是由于肝脏MLCL-AT蛋白表达的增加。结果表明,在肝脏再生过程中CL的从头生物合成及其再合成增加。